MBX Biosciences, Inc. Common Stock current ratio

The Current Ratio as of November 2026 (TTM) for MBX Biosciences, Inc. Common Stock (MBX) is 18.08

According to MBX Biosciences, Inc. Common Stock’s latest financial reports and current stock price. The company's current Current Ratio is 18.08. This represents a change of -32.05% compared to the average of 26.61 of the last 4 quarters.

MBX Biosciences, Inc. Common Stock (MBX) Historical Current Ratio (quarterly & annually)

How has MBX Current Ratio performed in the past?

The mean historical Current Ratio of MBX Biosciences, Inc. Common Stock over the last ten years is 20.74. The current 18.08 Current Ratio has changed -12.80% with respect to the historical average. Over the past ten years (40 quarters), MBX's Current Ratio was at its highest in in the September 2025 quarter at 32.95. The Current Ratio was at its lowest in in the March 2023 quarter at 0.

MBX Biosciences, Inc. Common Stock (MBX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of MBX Biosciences, Inc. Common Stock Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

MBX Biosciences, Inc. Common Stock (MBX) Average Current Ratio

How has MBX Current Ratio performed in the past?

The current Current Ratio of MBX Biosciences, Inc. Common Stock (MBX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

MBX Biosciences, Inc. Common Stock (MBX) Current Ratio vs. Peers

How is MBX’s Current Ratio compared to its peers?

MBX Biosciences, Inc. Common Stock’s Current Ratio is greater than Viking Therapeutics, Inc. (7.27), less than Altimmune, Inc. (26.78), greater than Skye Bioscience, Inc. (0.95), greater than Biomea Fusion, Inc. (3.47), greater than Rhythm Pharmaceuticals, Inc. (3.45), greater than Kailera Therapeutics, Inc. (11.11), greater than Oramed Pharmaceuticals Inc. (4.98), greater than Lipocine Inc. (11.48), greater than Xeris Biopharma Holdings, Inc. (1.45), greater than Ascendis Pharma A/S (2.99),

Build a custom stock screener for MBX Biosciences, Inc. Common Stock (MBX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MBX Biosciences, Inc. Common Stock using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MBX Biosciences, Inc. Common Stock (MBX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MBX Biosciences, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.